Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Regenacy Pharmaceuticals is raising $9,999,999.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Simon Jones played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Regenacy Pharmaceuticals
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function. We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.

To learn more about Regenacy Pharmaceuticals, visit http://regenacy.com/

Contact:
Simon Jones, President and Chief Executive Officer
617-415-5030
sjones@regenacy.com
https://www.linkedin.com/in/simon-jones-ph-d-09ab12b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved